Oncocyte Receivables

The latest receivables for OCX is $160K as of March 2026. That compares with $3.5M in the prior-year period — down 95.6% year over year. Investors often review this figure alongside Oncocyte's historical trend and sector peers before judging valuation or financial health.

Over the past year, OCX's receivables moved from $3.5M to $160K — a 95.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Oncocyte's operating scale or balance-sheet position.

A receivables figure of $160K for OCX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting OCX's receivables ($160K), review year-over-year change from $3.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Oncocyte's receivables against similar Technology names. You can also browse sector and industry screens on Stockcircle for a broader set of Technology companies and their key multiples and fundamentals.